

CITATION REPORT

List of articles citing

Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)

DOI: 10.1007/s40259-018-0285-2
BioDrugs, 2018, 32, 377-390.

Source: <https://exaly.com/paper-pdf/71716778/citation-report.pdf>

Version: 2024-04-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Potential safety signals with biologic use identified. <i>Reactions Weekly</i> , 2018 , 1707, 9-9	0	0
7	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019 , 14, 205-221	5	54
6	Thoracic Manifestations of Connective Tissue Diseases. <i>Seminars in Ultrasound, CT and MRI</i> , 2019 , 40, 239-254	1.7	4
5	Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 192-200.e2	3.3	6
4	Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e430-e431	4.6	1
3	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	13
2	Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®).	0	0
1	A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. 13,	0	0